SecurityNTC / Nuveen Connecticut Premium Income Municipal Fund, Inc. (67060D107)
Institutional Owners38
Institutional Shares3,388,562
Institutional Value$ 54,768,000 USD
Related NTC.PRC / Nuveen Connecticut Premium Income Municipal Fund, Inc.

Institutional Stock Ownership and Shareholders

NTC / Nuveen Connecticut Premium Income Municipal Fund, Inc. Institutional Ownership

Nuveen Connecticut Premium Income Municipal Fund, Inc. (NYSE:NTC) has 38 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,388,562 shares. Largest shareholders include Saba Capital Management, L.P., Bulldog Investors, LLC, Rivernorth Capital Management, Llc, Fiera Capital Corp, HighTower Advisors, LLC, Morgan Stanley, Commonwealth Equity Services, Inc, Commonwealth Equity Services, Llc., Greenwich Wealth Management LLC, and Sit Investment Associates Inc.
Nuveen Connecticut Premium Income Municipal Fund, Inc. (NYSE:NTC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 418 418 0.00 5 5 0.00
2018-08-13 13F-HR Catamount Wealth Management 7,308 7,308 0.00 84 85 1.19
2018-07-19 13F-HR SIT INVESTMENT ASSOCIATES INC 108,548 1,290
2018-08-08 13F-HR Bienville Capital Management, LLC 12,000 12,000 0.00 138 143 3.62
2018-08-13 13F-HR MML INVESTORS SERVICES, LLC 42,705 0 -100.00 491 0 -100.00
2018-08-13 13F-HR RAYMOND JAMES & ASSOCIATES 25,482 25,482 0.00 293 303 3.41
2018-08-03 13F-HR Clear Harbor Asset Management, LLC 17,569 16,739 -4.72 202 199 -1.49
2018-07-12 13F-HR WEBSTER BANK, N. A. 670 670 0.00 8 8 0.00
2018-08-20 13F-HR MASSMUTUAL TRUST CO FSB/ADV 1,215 14,434
2018-08-14 13F-HR Patriot Financial Group Insurance Agency, LLC 14,962 15,975 6.77 173 190 9.83
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 4,200 4,200 0.00 49 49 0.00
2018-08-14 13F-HR CNH PARTNERS LLC 26,387 26,387 0.00 304 313 2.96
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 85,135 95,490 12.16 979 1,134 15.83
2018-08-14 13F-HR Saba Capital Management, L.P. 230,509 973,058 322.13 2,658 11,560 334.91
2018-08-14 13F-HR Thomas J. Herzfeld Advisors, Inc. 13,200 0 -100.00 152 0 -100.00
2018-07-24 13F-HR Janney Montgomery Scott LLC 57,043 52,047 -8.76 656 618 -5.79
2018-08-13 13F-HR Bulldog Investors, LLC 298,595 348,717 16.79 3,434 4,174 21.55
2018-08-14 13F-HR HighTower Advisors, LLC 160,604 172,534 7.43 1,845 2,050 11.11
2018-07-25 13F-HR Greenwich Wealth Management LLC 123,069 127,239 3.39 1,415 1,512 6.86
2018-08-13 13F-HR Advisor Group, Inc. 2,753 709 -74.25 32 8 -75.00
2018-08-13 13F-HR RMB Capital Management, LLC 15,941 0 -100.00 183 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 225,139 166,068 -26.24 2,589 1,972 -23.83
2018-08-14 13F-HR ROYAL BANK OF CANADA 5,969 7,019 17.59 69 83 20.29
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 122,204 0 -100.00 1,409 0 -100.00
2018-08-02 13F-HR Fiera Capital Corp 156,000 196,000 25.64 1,794 2,328 29.77
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 0 26,710 0 317
2017-11-09 13F-HR TFS CAPITAL LLC 12,113 0 -100.00 150 0 -100.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 88,099 88,450 0.40 1,013 1,051 3.75
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 180,484 150,045 -16.87 2,231 1,832 -17.88
2018-08-13 13F-HR LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 70,192 25,197 -64.10 807 299 -62.95
2018-08-08 13F-HR Point View Wealth Management, Inc. 25,653 24,554 -4.28 295 292 -1.02
2018-08-08 13F-HR M&R CAPITAL MANAGEMENT INC 1,600 1,600 0.00 18 19 5.56
2018-08-14 13F-HR Walleye Trading LLC 42,308 503
2018-08-08 13F-HR Private Capital Group, Llc 3,897 3,897 0.00 45 46 2.22
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 15,586 0 -100.00 180 0 -100.00
2018-07-17 13F-HR Edge Wealth Management LLC 52,540 43,180 -17.81 604 513 -15.07
2018-08-10 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 0 500 0 6
2018-07-27 13F-HR Mathes Company, Inc. 14,000 26,500 89.29 161 315 95.65
2018-08-13 13F-HR Asset Dedication, LLC 14,505 0 -100.00 167 0 -100.00
2018-07-13 13F-HR Deschutes Portfolio Strategy, LLC 463,089 59,599 -87.13 5,326 708 -86.71
2018-08-14 13F-HR RIVERNORTH CAPITAL MANAGEMENT, LLC 239,235 2,842
2018-08-14 13F-HR DOLIVER CAPITAL ADVISORS, INC. 36,841 18,921 -48.64 424 225 -46.93
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 145,823 146,968 0.79 1,676 1,746 4.18
2017-01-13 13F-HR MetLife Securities, Inc 43,353 36,137 -16.64 599 444 -25.88
2018-08-14 13F-HR UBS Group AG 112,908 96,938 -14.14 1,298 1,152 -11.25
2018-08-08 13F-HR BRONFMAN E.L. ROTHSCHILD, L.P. 8,335 0 -100.00 96 0 -100.00

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 67060D107